Department of Surgery, Massachusetts General Hospital, Boston, MA; Department of Surgery, Harvard Medical School, Boston, MA. Electronic address: https://twitter.com/Dr_SwatiSonal.
Department of Surgery, Massachusetts General Hospital, Boston, MA.
Surgery. 2024 May;175(5):1285-1290. doi: 10.1016/j.surg.2024.01.007. Epub 2024 Feb 19.
Colorectal cancer remains the third leading cause of cancer-related mortality in the United States. This study evaluates the causes of death in patients operated on for colorectal cancer and their determinants.
An Instructional Review Board-approved database containing patients who underwent surgical resection for colorectal cancer from 2004 to 2018 (last followed up in December 2020) in a tertiary care institution. Data on the underlying cause of death was extracted from the Registry of Vital Records and Statistics in Massachusetts.
A total of 576 deaths were recorded in the database, of which 290 (50.35%) patients died of colorectal cancer. Deaths from colorectal cancer gradually decreased over time, whereas deaths from other cancers increased, and deaths from cardiovascular diseases remained stable. Patients who died from colorectal cancer were younger, died earlier in the disease course, had fewer comorbidities, higher rates of stage IV disease, rectal cancer, neoadjuvant therapy, extramural vascular invasion, perineural invasion, R0 resection, and preserved mismatch repair protein status. On multivariate analysis, age (adjusted odds ratio for 10-year increase = 0.79, 95% confidence interval 0.65-0.95), American Society of Anesthesiologists score (adjusted odds ratio = 0.64, confidence interval 0.42-0.98), stage IV disease (adjusted odds ratio = 3.02, confidence interval 1.59-5.9), neoadjuvant therapy (adjusted odds ratio = 7.91, confidence interval 2.64-28.13), extramural vascular invasion (adjusted odds ratio = 2.3, confidence interval 1.36-3.91) & time from diagnosis to death (adjusted odds ratio = 0.76, confidence interval 0.68-0.83) predicted death due to colorectal cancer versus other causes, whereas tumor location, perineural invasion, R0 resection, and mismatch repair protein status did not.
There is a declining trend of deaths from colorectal cancer, presumably reflecting advances in colorectal cancer management strategies and better screening over time. However, younger patients disproportionately contribute to death due to colorectal cancer and need aggressive screening and management strategies.
结直肠癌仍然是美国癌症相关死亡的第三大主要原因。本研究评估了接受结直肠癌手术患者的死亡原因及其决定因素。
对一家三级保健机构 2004 年至 2018 年(最后随访时间为 2020 年 12 月)接受结直肠切除术的患者进行指令审查委员会批准的数据库。从马萨诸塞州生命记录和统计登记处提取死亡的根本原因数据。
数据库中记录了 576 例死亡,其中 290 例(50.35%)患者死于结直肠癌。结直肠癌的死亡率随着时间的推移逐渐下降,而其他癌症的死亡率上升,心血管疾病的死亡率保持稳定。死于结直肠癌的患者年龄较小,疾病早期死亡,合并症较少,IV 期疾病、直肠癌、新辅助治疗、外膜血管侵犯、神经周围侵犯、RO 切除和错配修复蛋白状态保存的比例较高。多变量分析显示,年龄(每增加 10 年的调整优势比为 0.79,95%置信区间为 0.65-0.95)、美国麻醉师协会评分(调整优势比为 0.64,置信区间为 0.42-0.98)、IV 期疾病(调整优势比为 3.02,置信区间为 1.59-5.9)、新辅助治疗(调整优势比为 7.91,置信区间为 2.64-28.13)、外膜血管侵犯(调整优势比为 2.3,置信区间为 1.36-3.91)和诊断至死亡的时间(调整优势比为 0.76,置信区间为 0.68-0.83)预测结直肠癌死亡与其他原因,而肿瘤位置、神经周围侵犯、RO 切除和错配修复蛋白状态则不然。
结直肠癌死亡呈下降趋势,这可能反映了结直肠癌管理策略的进步和随着时间的推移更好的筛查。然而,年轻患者不成比例地导致结直肠癌死亡,需要积极的筛查和管理策略。